Immunocore (NASDAQ:IMCR) Insider David Berman Sells 5,965 Shares

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider David Berman sold 5,965 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the transaction, the insider owned 5,859 shares in the company, valued at approximately $189,538.65. This trade represents a 50.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Immunocore Price Performance

Shares of NASDAQ:IMCR traded up $0.66 on Thursday, reaching $33.17. 392,220 shares of the company traded hands, compared to its average volume of 465,558. The stock has a market capitalization of $1.68 billion, a PE ratio of -58.19 and a beta of 0.78. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The company’s 50 day moving average is $33.94 and its 200-day moving average is $34.31. Immunocore Holdings PLC Sponsored ADR has a fifty-two week low of $23.15 and a fifty-two week high of $40.71.

Institutional Trading of Immunocore

Hedge funds have recently made changes to their positions in the stock. Leonteq Securities AG purchased a new position in Immunocore during the fourth quarter valued at approximately $30,000. GAMMA Investing LLC grew its holdings in shares of Immunocore by 51.6% during the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after acquiring an additional 311 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after acquiring an additional 388 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Immunocore by 4,696.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after acquiring an additional 1,268 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Immunocore during the second quarter worth $42,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IMCR has been the subject of a number of recent analyst reports. Morgan Stanley increased their price target on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Wells Fargo & Company assumed coverage on shares of Immunocore in a research report on Friday, October 31st. They issued an “overweight” rating and a $60.00 target price on the stock. UBS Group set a $55.00 price target on shares of Immunocore and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.90.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.